Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 216

1.

Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.

Vāvere AL, Lewis JS.

Dalton Trans. 2007 Nov 21;(43):4893-902. Epub 2007 Sep 25.

PMID:
17992274
[PubMed - indexed for MEDLINE]
2.

Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).

Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW.

J Nucl Med. 2006 Jun;47(6):989-98.

PMID:
16741309
[PubMed - indexed for MEDLINE]
Free Article
3.

Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.

Bonnitcha PD, Bayly SR, Theobald MB, Betts HM, Lewis JS, Dilworth JR.

J Inorg Biochem. 2010 Feb;104(2):126-35. doi: 10.1016/j.jinorgbio.2009.10.009. Epub 2009 Oct 24.

PMID:
19932509
[PubMed - indexed for MEDLINE]
4.

Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix.

Grigsby PW, Malyapa RS, Higashikubo R, Schwarz JK, Welch MJ, Huettner PC, Dehdashti F.

Mol Imaging Biol. 2007 Sep-Oct;9(5):278-83.

PMID:
17431727
[PubMed - indexed for MEDLINE]
5.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502.

PMID:
15817355
[PubMed - indexed for MEDLINE]
6.

A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.

Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1171-82.

PMID:
11240261
[PubMed - indexed for MEDLINE]
7.

An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix.

Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA.

J Nucl Med. 2008 Jul;49(7):1177-82. doi: 10.2967/jnumed.108.051326. Epub 2008 Jun 13.

PMID:
18552145
[PubMed - indexed for MEDLINE]
Free Article
8.

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ.

J Nucl Med. 2008 Feb;49(2):201-5. doi: 10.2967/jnumed.107.048520. Epub 2008 Jan 16.

PMID:
18199612
[PubMed - indexed for MEDLINE]
Free Article
9.

Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8.

PMID:
12654432
[PubMed - indexed for MEDLINE]
10.

Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.

Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA.

Dis Colon Rectum. 2008 Nov;51(11):1641-8. doi: 10.1007/s10350-008-9420-3. Epub 2008 Aug 6.

PMID:
18682881
[PubMed - indexed for MEDLINE]
11.

Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone).

Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R, Kovacs A, Gropler RJ, Welch MJ.

J Nucl Med. 2002 Nov;43(11):1557-69.

PMID:
12411560
[PubMed - indexed for MEDLINE]
Free Article
12.

Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning.

Myerson RJ, Singh AK, Bigott HM, Cha B, Engelbach JA, Kim J, Lamoreaux WT, Moros E, Novak P, Sharp TL, Straube W, Welch MJ, Xu M.

Int J Hyperthermia. 2006 Mar;22(2):93-115.

PMID:
16754595
[PubMed - indexed for MEDLINE]
13.

Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals.

Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE.

J Med Chem. 2002 Mar 28;45(7):1420-31.

PMID:
11906283
[PubMed - indexed for MEDLINE]
14.

Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ.

J Nucl Med. 2001 Apr;42(4):655-61.

PMID:
11337556
[PubMed - indexed for MEDLINE]
Free Article
15.

Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging.

Jalilian AR, Rostampour N, Rowshanfarzad P, Shafaii K, Kamali-Dehghan M, Akhlaghi M.

Acta Pharm. 2009 Mar;59(1):45-55. doi: 10.2478/v10007-009-0008-9.

PMID:
19304557
[PubMed - indexed for MEDLINE]
16.

Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model.

Oh M, Tanaka T, Kobayashi M, Furukawa T, Mori T, Kudo T, Fujieda S, Fujibayashi Y.

Nucl Med Biol. 2009 May;36(4):419-26. doi: 10.1016/j.nucmedbio.2009.01.016. Epub 2009 Mar 26.

PMID:
19423010
[PubMed - indexed for MEDLINE]
17.

Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.

Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, Okazawa H.

J Nucl Med. 2009 Dec;50(12):1948-53. doi: 10.2967/jnumed.109.069021. Epub 2009 Nov 12.

PMID:
19910425
[PubMed - indexed for MEDLINE]
Free Article
18.

In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA.

Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):844-50. Epub 2003 Apr 12.

PMID:
12692685
[PubMed - indexed for MEDLINE]
19.

Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.

Holland JP, Lewis JS, Dehdashti F.

Q J Nucl Med Mol Imaging. 2009 Apr;53(2):193-200. Review.

PMID:
19293767
[PubMed - indexed for MEDLINE]
Free Article
20.

Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.

Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi C, Fazio F, Picchio M, Moresco RM.

J Nucl Med. 2013 Jul;54(7):1106-12. doi: 10.2967/jnumed.112.111120. Epub 2013 May 22.

PMID:
23699667
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk